The dual EGF/VEGF receptor tyrosine kinase inhibitor AEE788 inhibits growth of human hepatocellular carcinoma xenografts in nude mice

Matthias Ocker(Unknown)

International Journal of Oncology

January 1, 1992

10.3892/ijo_00000059

Cited by 23

Related Papers

BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models

|Nature Cancer|2024|28

ANJ810 is a novel highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models

|Research Square|2023|1

Abstract 506: ANJ810 is a highly selective novel MCL1 inhibitor with optimized in vivo clearance showing robust efficacy in preclinical solid and hematological tumor models

|Cancer Research|2023|1